Driving Efficacy, Stability & Immunogenicity to Unlock the Full Clinical Potential of Circular & Self-Amplifying RNA Therapeutics
The 5th Circular & Self-Amplifying RNA Therapeutics Summit is the only industry forum dedicated exclusively to translating circRNA and saRNA into durable, IND-ready medicines. As the RNA field moves beyond linear mRNA, these next-generation modalities are emerging as the solution to short-lived expression, high dosing requirements, and limited therapeutic reach.
With first-in-human trials now underway, increasing regulatory engagement, and expanding applications across oncology, autoimmune disease, and in vivo CAR-T, 2026 represents a critical inflection point. Developers must now prove not just promise, but performance, from durability and immunogenicity control to delivery, manufacturability, and IP strategy.
Held in Boston from May 26–28, 2026, this summit brings together senior leaders from biotech, pharma, and academia, including teams from CirCode Biomed, Replicate Bioscience, Sail Biomedicines, Strand Therapeutics, HDT Bio, and Altamira Therapeutics. Across data-driven case studies, expert panels, and deep-dive workshops, attendees will gain practical insight into advancing circular and self-amplifying RNA programs toward the clinic.
If you are building, validating, or scaling next-generation m-RNA platforms, this is the definitive meeting to attend in 2026.
This meeting provides an exciting opportunity to share our emerging insights, challenge assumptions, and help shape the direction of the rapidly developing new modalities
Joshua McGee, Co-Founder & Chief Scientific Officer, Keylicon Bio
“This meeting is a great opportunity to communicate with the RNA community, share thoughts and build the ecosystem”
Chenxiang Tang, Chief Executive Officer, CirCode Biomed
“This meeting brings together RNA scientists, technologies, and translational insights - enabling critical cross-pollination of ideas, catalyzing collaboration, and accelerating the next wave of clinical and technological breakthroughs”
Thimmaiah Chendrimada, Co-Founder & Chief Scientific Officer, Able Sciences
- 60+ RNA Innovators from leading biotech, pharma & academia
- 16+ Expert Speakers driving circRNA & saRNA clinical translation
- 15+ Data-Led Case Studies spanning discovery to IND execution
- 8+ Hours of Structured Networking with senior RNA decision-makers
- 2 Deep-Dive Workshops tackling immunogenicity, dosing & CMC strategy
Attending Companies Include
Explore Related Events
Explore the Agenda
Dive into data-driven sessions tackling durability, delivery, immunogenicity, and IND readiness for circular and self-amplifying RNA.
Partner With Us
Connect with RNA developers actively seeking solutions across discovery, delivery, manufacturing, and regulatory strategy.
Join Biopharma Experts
Network with the scientists and leaders shaping the next wave of RNA medicines beyond linear mRNA.